Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1998 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
1.–5. rezultāts no 100.
204. lappuse
... injection . ( 2 ) If the formulation of the test arti- cle differs from the formulation ( s ) used in the clinical studies demonstrating substantial evidence of safety and ef- fectiveness for the test article's claimed indications , a ...
... injection . ( 2 ) If the formulation of the test arti- cle differs from the formulation ( s ) used in the clinical studies demonstrating substantial evidence of safety and ef- fectiveness for the test article's claimed indications , a ...
299. lappuse
... injection means the insulin injection recognized in the U.S.P. ( i ) The term protamine zinc insulin suspension means the protamine zinc insulin suspension recognized in the U.S.P. ( j ) The term globin zinc insulin injec- tion means ...
... injection means the insulin injection recognized in the U.S.P. ( i ) The term protamine zinc insulin suspension means the protamine zinc insulin suspension recognized in the U.S.P. ( j ) The term globin zinc insulin injec- tion means ...
300. lappuse
... injection ; ( 6 ) A statement that failure to com- ply with the techniques described in paragraphs ( c ) ( 3 ) , ( 4 ) , and ( 5 ) of this section may lead to infection of the pa- tient ; ( 7 ) A statement that injection should be ...
... injection ; ( 6 ) A statement that failure to com- ply with the techniques described in paragraphs ( c ) ( 3 ) , ( 4 ) , and ( 5 ) of this section may lead to infection of the pa- tient ; ( 7 ) A statement that injection should be ...
301. lappuse
... injection ( in addition to the in- formation required by paragraphs ( a ) , ( b ) , and ( c ) or ( i ) of this section ) , a cau- tion against use if the drug has become viscous or if its color has become other than water clear . ( e ) ...
... injection ( in addition to the in- formation required by paragraphs ( a ) , ( b ) , and ( c ) or ( i ) of this section ) , a cau- tion against use if the drug has become viscous or if its color has become other than water clear . ( e ) ...
302. lappuse
... injection shall be dis- tinguished by the following colors : Red , if it contains 40 U.S.P. Units of insu- lin per milliliter . White , if it contains 100 U.S.P. Units of in- sulin per milliliter . Narrow ( at least 5 but not more than ...
... injection shall be dis- tinguished by the following colors : Red , if it contains 40 U.S.P. Units of insu- lin per milliliter . White , if it contains 100 U.S.P. Units of in- sulin per milliliter . Narrow ( at least 5 but not more than ...
Saturs
279 | |
285 | |
290 | |
299 | |
310 | |
331 | |
339 | |
340 | |
223 | |
236 | |
238 | |
239 | |
240 | |
256 | |
257 | |
262 | |
263 | |
265 | |
270 | |
275 | |
351 | |
483 | |
588 | |
593 | |
696 | |
699 | |
761 | |
826 | |
865 | |
890 | |
911 | |
949 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient adverse drug experience agency amended antibiotic application or abbreviated bacitracin bioavailability bioequivalence cation Center for Drug certification chapter clinical hold clinical investigation conducted control number copy Cosmetic Act digoxin dosage form dose Drug Administration drug application Drug Evaluation drug prod drug product Drug products containing drug substance Evaluation and Research Federal Food Food and Drug graph gredients hearing hydrochloride identified information requirements ap insulin intended inves investigational new drug labeling manufacturer marketing meet ment milligrams milliliters misbranded neomycin notice oral dosage orphan drug OTC drug product package paragraph percent person plication polymyxin proposed protocol recognized as safe reference listed drug request safe and effective safety section 502 Sodium sponsor statement submission Subpart sulfate tained tigational tion tive treatment treatment IND vestigational viated warning